Latest Health News and Insights

Recurrent glioblastoma treatment research is exploring D2C7-ATC, an experimental therapy targeting EGFR and EGFRvIII through direct delivery into the tumour. This patient-focused review explains the Phase 1 survival and safety findings, exploratory biomarkers, study limitations and essential questions families should discuss with a specialist neuro-oncology team.

Vaginal laser for breast cancer survivors taking aromatase inhibitors did not improve sexual function, painful intercourse or vaginal health more than sham treatment at 12 months, according to a randomized clinical trial. Both groups improved while receiving nonhormonal supportive care, raising important questions about the cost and additional value of vaginal laser procedures.

Daraxonrasib pancreatic cancer trial results could change treatment decisions for adults with previously treated metastatic pancreatic adenocarcinoma. In RASolute 302, Rasonque increased median overall survival to 13.2 months versus 6.7 months with chemotherapy. This patient guide explains eligibility, benefits, response rates, side effects, interactions and what the EMA recommendation means for access in Europe.

Ph-positive ALL treatment using ponatinib plus blinatumomab achieved an estimated 86% two-year event-free survival in the Phase III GIMEMA ALL2820 trial, compared with 67% for imatinib plus chemotherapy. This patient guide explains who the findings apply to, what chemotherapy-free treatment involves, potential risks, relapse monitoring and why event-free survival does not guarantee a permanent cure.

Everest cumin powder recall has raised concerns about azoxystrobin and thiamethoxam exposure after FSSAI ordered Batch E080668761 withdrawn. This patient-focused guide explains how these pesticides may affect the liver, kidneys, nervous system, blood and reproductive organs, which risks are supported by human or animal evidence, who may be more vulnerable, and when consumers should seek medical care.

Platinum-resistant ovarian cancer treatment is entering a new research phase with Rina-S, an investigational FRα-targeted antibody-drug conjugate that reported a 45.9% response rate in RAINFOL-01. This patient-focused update explains the trial results, safety concerns, FRα findings, prior-treatment relevance, and why Phase 3 confirmation is essential before Rina-S can be considered a proven standard option.

A new thyroid nodule blood test using serum thyroid-hormone metabolites showed 92.1% sensitivity and 99.7% specificity for differentiated thyroid cancer. The study may offer future diagnostic support for patients with indeterminate Bethesda III–IV nodules, although ultrasound, fine-needle aspiration biopsy and specialist evaluation remain essential.

Ashwagandha safety trial findings from India offer reassuring data on a standardized root extract used for 24 weeks in 1,200 adults. The study found no treatment-related serious liver or kidney injury, but mild liver enzyme elevations were still reported, making product quality, patient selection and medical supervision important.

False positive mammogram breast cancer risk may be higher than previously understood. A major analysis involving nearly 4.9 million women found a 77% higher relative rate of subsequent breast cancer. Understand what this finding means, why a false positive does not cause cancer, and how personalised screening and risk assessment may help guide future care.

Mycotoxins in food may be present in grains, nuts, seeds, spices, meat and botanical products. A randomized German trial found different urinary exposure patterns in vegan and meat-rich diets, but it did not prove toxicity. Learn what these findings mean, which foods require closer attention, and how safer storage, dietary variety and quality-controlled herbal products may help reduce exposure.

Ayurveda pharmacovigilance is becoming essential for patients using Ayurvedic medicines alongside diabetes, heart, cancer, autoimmune or other chronic disease treatments. India’s renewed safety focus highlights herb–drug interactions, adverse reactions, herbo-mineral medicine quality and the need for evidence-backed monitoring.

WHO’s 2025–2034 traditional medicine research agenda could reshape how Ayurveda is studied, regulated and integrated into healthcare. This patient-focused guide explains the evidence gap, safety priorities, India’s research role and what the WHO roadmap means when choosing responsible, evidence-informed Ayurvedic care.

Lenacapavir HIV prevention is becoming more accessible across 14 Latin American countries through a new PAHO procurement pathway. The twice-yearly injectable PrEP option may help people who struggle with daily tablets, privacy concerns or adherence, while still requiring proper HIV testing, clinical eligibility review and national programme approval.

Time restricted eating for weight loss is one of the most searched diet approaches worldwide. A new pooled analysis of five clinical trials suggests that an 8 hour eating window may lead to slightly greater weight loss than longer eating windows, especially compared with a 12 hour schedule. The findings are promising, but they do not mean that every patient should follow strict 16:8 fasting. Ayurveda also emphasizes meal timing, digestion, metabolic rhythm and individual body strength, making personalized guidance important before starting fasting for weight loss.

Hidden drugs in herbal supplements can expose patients to undeclared pharmaceutical compounds without dosage control, medical screening or interaction warnings. Indonesia BPOM has identified pyrimidenafil in three male-stamina products and reported several other illegal herbal and supplement products containing hidden drugs, raising important safety questions for patients using online “natural” remedies.

West Nile virus Europe 2026 has become a major mosquito borne disease concern, with 1,086 locally acquired cases and 61 deaths reported across 15 European countries. This patient focused update explains the affected countries, warning symptoms, neurological risks and practical mosquito protection steps for residents and travelers.

A new Phase 3 clinical trial found that a standardized traditional herbal extract improved 28-day passage of selected 5–10 mm ureteral stones compared with placebo. This patient-friendly guide explains the result, safety limits, Ayurveda’s view of Mutrashmari and practical prevention after stone passage.

Infections in pregnancy may be silent, but some can pass from mother to baby. HIV, syphilis and hepatitis B testing early in pregnancy gives doctors time to plan treatment, safe delivery care and newborn protection before harm occurs.

Hidden drugs in weight loss supplements may expose consumers to banned or prescription medicines without their knowledge. Singapore’s Health Sciences Authority found sibutramine, fluoxetine, two diuretics, orlistat and bisacodyl in an online weight loss product. Learn the possible symptoms, serious health risks, when to seek urgent medical care and how to identify safer weight management products.